New Drug Combo Delayed Disease Progression for Subgroup of Women With Metastatic Breast Cancer

December 13, 2013

Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II study. Investigator Dev Paul, DO, PhD, of Rocky Mountain Cancer Centers cautioned that more information is needed to determine which patients will benefit from the addition of dasatinib.

Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II study. Investigator Dev Paul, DO, PhD, of Rocky Mountain Cancer Centers cautioned that more information is needed to determine which patients will benefit from the addition of dasatinib.